The peripheral blood Valpha24+ NKT cell numbers decrease in patients with haematopoietic malignancy.

[1]  L. Kaer,et al.  NKT cells: what's in a name? , 2004, Nature Reviews Immunology.

[2]  S. Nimer,et al.  Severe and selective deficiency of interferon‐γ‐producing invariant natural killer T cells in patients with myelodysplastic syndromes , 2003, British journal of haematology.

[3]  M. Dhodapkar,et al.  A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma , 2003, The Journal of experimental medicine.

[4]  M. Nozue,et al.  Impaired Proliferative Response of Vα24 NKT Cells from Cancer Patients Against α-Galactosylceramide1 , 2002, The Journal of Immunology.

[5]  H. Hirai,et al.  Cutting Edge: Analysis of Human Vα24+CD8+ NK T Cells Activated by α-Galactosylceramide-Pulsed Monocyte-Derived Dendritic Cells , 2002, The Journal of Immunology.

[6]  L. Teyton,et al.  Distinct Functional Lineages of Human Vα24 Natural Killer T Cells , 2002, The Journal of experimental medicine.

[7]  Takashi Yamamura,et al.  Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer Staining , 2002, The Journal of experimental medicine.

[8]  G. Bubley,et al.  Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer1 , 2001, The Journal of Immunology.

[9]  T. Sumida,et al.  Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. , 2001, Arthritis and rheumatism.

[10]  K. Tadokoro,et al.  α-Glycosylceramides Enhance the Antitumor Cytotoxicity of Hepatic Lymphocytes Obtained from Cancer Patients by Activating CD3−CD56+ NK Cells In Vitro , 2000, The Journal of Immunology.

[11]  H. Macdonald,et al.  Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells , 2000, European journal of immunology.

[12]  T. Iizasa,et al.  Antitumor Cytotoxicity Mediated by Ligand-activated Human Vα24 NKT Cells , 1999 .

[13]  M. Taniguchi,et al.  Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide. , 1999, Journal of immunology.

[14]  K. Tadokoro,et al.  Activation of human Vα24NKT cells by α-glycosylceramide in a CD1d-restricted and Vα24TCR-mediated manner , 1999 .

[15]  T. Sumida,et al.  TCR AV24 gene expression in double negative T cells in systemic lupus erythematosus , 1998, Lupus.

[16]  Y. Tanaka,et al.  Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Nakagawa,et al.  Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. , 1998, Cancer research.

[18]  D. Hafler,et al.  Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes , 1998, Nature.

[19]  Hiroshi Sato,et al.  CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. , 1997, Science.

[20]  T. Sumida,et al.  Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis , 1995, The Journal of experimental medicine.

[21]  T. Natori,et al.  Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. , 1995, Journal of medicinal chemistry.

[22]  K. Sugamura,et al.  Differential expression of the interleukin 2 receptor beta (p75) chain on human peripheral blood natural killer subsets. , 1990, International immunology.